Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2013; 110(04): 623-625
DOI: 10.1160/TH13-08-0677
DOI: 10.1160/TH13-08-0677
Editorial Focus
Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy
Authors
Further Information
Publication History
Received:
19 August 2013
Accepted:
20 August 2013
Publication Date:
01 December 2017 (online)
Editorial Focus on: Bernard et al. Thromb Haemost 2013; 110: 560–568.
-
References
- 1 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study.. Thromb Haemost 2011; 106: 739-749.
- 2 Friberg LRM, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation.. Circulation 2012; 125: 2298-2307.
- 3 Rodríguez-Mañero M, Cordero A, BertomeuGonzález V. et al. Impacto de los nuevos criterios para el tratamiento anticoagulante de la fibrilación auricular.. Rev Esp Cardiol 2011; 64: 649-653.
- 4 Wilke T, Groth A, Mueller S. et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients.. Thromb Haemost 2012; 107: 1053-1065.
- 5 Olesen JB, Torp-Pedersen C, Hansen ML. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study.. Thromb Haemost 2012; 107: 1172-1179.
- 6 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study.. Thromb Haemost 2011; 106: 739-749.
- 7 Mehta RH, Dabbous OH, Granger CB. et al; GRACE Investigators. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation.. Am J Cardiol 2003; 92: 1031-1036.
- 8 Lip GY, Andreotti F, Fauchier L. et al; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis.. Thromb Haemost 2011; 106: 997-1011.
- 9 Lip GY, Huber K, Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting.. Thromb Haemost 2010; 103: 13-28.
- 10 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.. Thromb Haemost 2011; 106: 572-584.
- 11 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe.. Thromb Haemost 2011; 106: 569-571.
- 12 Bernard A, Fauchier L, Pellegrin C. et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation.. Thromb Haemost 2013; 110: 560-568.
- 13 Ruiz-Nodar JM, Marín F, Manzano-Fernandez S. et al. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization.. Chest 2011; 139: 1402-1409.
- 14 Ruiz-Nodar JM, Marín F, Sánchez-Payá J. et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation.. Eur Heart J 2009; 30: 932-939.
- 15 Lamberts M, Olesen JB, Ruwald MH. et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.. Circulation. 2012; 126: 1185-1193.
- 16 Dewilde WJ, Oirbans T, Verheught FW. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial.. Lancet 2013; 381: 1107-1115.
- 17 Manzano-Fernandez S, Pastor FJ, Marín F. et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.. Chest 2008; 134: 559-567.
- 18 Azoulay L, Dell’Aniello S, Simon T. et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation.. Thromb Haemost 2013; 109: 431-439.
- 19 Manzano-Fernández S, Cambronero F, Caro-Martínez C. et al. Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting.. Thromb Haemost 2012; 107: 51-58.
- 20 Smith JG, Wieloch M, Koul S. et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.. EuroIntervention 2012; 8: 672-678.
- 21 Ruiz-Nodar JM, Marín F. Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions.. Thromb Haemost 2013; 109: 363-365.
- 22 Brugaletta S, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives.. Expert Rev Med Devices 2012; 9: 327-38.
- 23 Colmenarez H, Fernández C, Escaned J. Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first- and second-generation drug-eluting stents.. EuroIntervention. 2013 Epub ahead of print.
- 24 Costopoulos C, Latib A, Naganuma T. et al. Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations.. Catheter Cardiovasc Interv. 2013 Epub ahead of print.
- 25 Banerjee A, Lane D, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modeling analysis based on a nationwide cohort study.. Thromb Haemost 2012; 107: 584-589.
- 26 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.. Thromb Haemost 2012; 107: 838-847.
- 27 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.. Eur Heart J 2012; 33: 2719-2747.
- 28 Kirchhof P, Lip GY, Van Gelder IC. et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference.. Thromb Haemost 2011; 106: 1012-1019.